• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Long-term follow-up of VIALE-C in patients with untreated AML ineligible for intensive chemotherapy.

作者信息

Wei Andrew H, Panayiotidis Panayiotis, Montesinos Pau, Laribi Kamel, Ivanov Vladimir, Kim Inho, Novak Jan, Champion Rebecca, Fiedler Walter, Pagoni Maria, Bergeron Julie, Ting Stephen B, Hou Jing-Zhou, Anagnostopoulos Achilles, McDonald Andrew, Murthy Vidhya, Yamauchi Takahiro, Wang Jianxiang, Jiang Qi, Sun Yan, Chyla Brenda, Mendes Wellington, DiNardo Courtney D

机构信息

The Peter MacCallum Cancer Centre, Royal Melbourne Hospital and Walter and Eliza Hall Institute of Medical Research, Melbourne, Victoria, Australia.

National and Kapodistrian University of Athens Medical School, Laiko General Hospital, Athens, Greece.

出版信息

Blood. 2022 Dec 22;140(25):2754-2756. doi: 10.1182/blood.2022016963.

DOI:10.1182/blood.2022016963
PMID:36112968
Abstract
摘要

相似文献

1
Long-term follow-up of VIALE-C in patients with untreated AML ineligible for intensive chemotherapy.VIALE-C研究对不符合强化化疗条件的初治急性髓系白血病患者的长期随访
Blood. 2022 Dec 22;140(25):2754-2756. doi: 10.1182/blood.2022016963.
2
Venetoclax plus low-dose cytarabine in patients with newly diagnosed acute myeloid leukemia ineligible for intensive chemotherapy: an expanded access study in Japan.维奈克拉联合低剂量阿糖胞苷治疗不适合强化化疗的新诊断急性髓系白血病患者：日本扩展准入研究。
Jpn J Clin Oncol. 2023 Jun 29;53(7):595-603. doi: 10.1093/jjco/hyad027.
3
Venetoclax plus low-dose cytarabine in Japanese patients with untreated acute myeloid leukaemia ineligible for intensive chemotherapy.维奈克拉联合小剂量阿糖胞苷治疗不适合强化化疗的初治急性髓系白血病日本患者。
Jpn J Clin Oncol. 2021 Aug 30;51(9):1372-1382. doi: 10.1093/jjco/hyab112.
4
6-month follow-up of VIALE-C demonstrates improved and durable efficacy in patients with untreated AML ineligible for intensive chemotherapy (141/150).VIALE-C 的 6 个月随访结果显示，对于不适合强化化疗的未经治疗的 AML 患者（141/150），疗效得到改善且持久。
Blood Cancer J. 2021 Oct 1;11(10):163. doi: 10.1038/s41408-021-00555-8.
5
Venetoclax for the treatment of elderly or chemotherapy-ineligible patients with acute myeloid leukemia: a step in the right direction or a game changer?维奈托克用于治疗老年或不适合化疗的急性髓系白血病患者：是朝着正确方向迈出的一步还是改变游戏规则的药物？
Expert Rev Hematol. 2021 Feb;14(2):199-210. doi: 10.1080/17474086.2021.1876559. Epub 2021 Feb 8.
6
Long-term follow-up of VIALE-A: Venetoclax and azacitidine in chemotherapy-ineligible untreated acute myeloid leukemia.VIALE-A 研究的长期随访：不适合化疗的初治急性髓系白血病患者中应用维奈克拉联合阿扎胞苷。
Am J Hematol. 2024 Apr;99(4):615-624. doi: 10.1002/ajh.27246. Epub 2024 Feb 11.
7
Venetoclax combined with hypomethylating agents or low-dose cytarabine as induction chemotherapy for patients with untreated acute myeloid leukemia ineligible for intensive chemotherapy: a systematic review and meta-analysis.维奈托克联合低剂量阿糖胞苷或去甲基化药物作为不适合强化化疗的未经治疗的急性髓系白血病患者的诱导化疗：系统评价和荟萃分析。
Clin Exp Med. 2023 Jun;23(2):219-227. doi: 10.1007/s10238-021-00784-y. Epub 2022 Jan 23.
8
Venetoclax combinations delay the time to deterioration of HRQoL in unfit patients with acute myeloid leukemia.维奈托克联合疗法可延缓不适合接受治疗的急性髓系白血病患者健康相关生活质量恶化的时间。
Blood Cancer J. 2022 Apr 20;12(4):71. doi: 10.1038/s41408-022-00668-8.
9
Glasdegib plus intensive/nonintensive chemotherapy in untreated acute myeloid leukemia: BRIGHT AML 1019 Phase III trials.玻璃化酶联合强化/非强化化疗治疗未经治疗的急性髓细胞白血病：BRIGHT AML 1019 期临床试验。
Future Oncol. 2019 Nov;15(31):3531-3545. doi: 10.2217/fon-2019-0373. Epub 2019 Sep 13.
10
Real-world outcomes of frontline venetoclax-based therapy in older adults with acute myeloid leukemia: an analysis utilizing EHR data.基于 Venetoclax 的一线治疗在老年急性髓系白血病患者中的真实世界结局：利用电子健康记录数据进行的分析。
Leuk Lymphoma. 2023 Jun;64(6):1123-1128. doi: 10.1080/10428194.2023.2197090. Epub 2023 Apr 13.

引用本文的文献

1
Apoptosis-targeting BH3 mimetics: transforming treatment for patients with acute myeloid leukaemia.靶向凋亡的BH3模拟物：改变急性髓系白血病患者的治疗方式
Nat Rev Clin Oncol. 2025 Sep 1. doi: 10.1038/s41571-025-01068-0.
2
Feasibility and Safety of Targeting Mitochondria Function and Metabolism in Acute Myeloid Leukemia.靶向急性髓系白血病线粒体功能和代谢的可行性与安全性
Curr Pharmacol Rep. 2024 Dec;10(6):388-404. doi: 10.1007/s40495-024-00378-8. Epub 2024 Oct 4.
3
Real-world outcomes of newly diagnosed AML treated with venetoclax and azacitidine or low-dose cytarabine in the UK NHS.
在英国国家医疗服务体系（NHS）中，使用维奈克拉和阿扎胞苷或小剂量阿糖胞苷治疗新诊断急性髓系白血病（AML）的真实世界疗效。
Blood Neoplasia. 2024 May 23;1(3):100017. doi: 10.1016/j.bneo.2024.100017. eCollection 2024 Sep.
4
Advances in the Treatment of Acute Myeloid Leukemia: Implications for Low- and Middle-Income Countries.急性髓系白血病治疗进展：对低收入和中等收入国家的影响
Biomedicines. 2025 May 18;13(5):1221. doi: 10.3390/biomedicines13051221.
5
Comparing the efficacy and safety of venetoclax combined with hypomethylating agents versus intensive chemotherapy as induction therapy in newly diagnosed core binding factor acute myeloid leukemia patients.比较维奈克拉联合低甲基化药物与强化化疗作为初诊核心结合因子急性髓系白血病患者诱导治疗的疗效和安全性。
Blood Cancer J. 2025 Feb 11;15(1):17. doi: 10.1038/s41408-025-01227-7.
6
Clinical interrogation of aberrations and its impact on survival in patients with myeloid neoplasms.髓系肿瘤患者畸变的临床问诊及其对生存的影响。
Haematologica. 2025 Jun 1;110(6):1304-1315. doi: 10.3324/haematol.2024.286465. Epub 2024 Dec 12.
7
The impact of post-remission granulocyte colony-stimulating factor use in the phase 3 studies of venetoclax combination treatments in patients with newly diagnosed acute myeloid leukemia.缓解后使用粒细胞集落刺激因子在维奈克拉联合治疗新诊断急性髓系白血病患者的3期研究中的影响
Am J Hematol. 2025 Jan;100(1):185-188. doi: 10.1002/ajh.27515. Epub 2024 Nov 1.
8
Mitochondria and Acute Leukemia: A Clinician's Perspective.线粒体与急性白血病：临床视角
Int J Mol Sci. 2024 Sep 7;25(17):9704. doi: 10.3390/ijms25179704.
9
Lower intensity therapy with cladribine/low dose cytarabine/venetoclax in older patients with acute myeloid leukemia compares favorably with intensive chemotherapy among patients undergoing allogeneic stem cell transplantation.在接受异基因干细胞移植的患者中，与强化化疗相比，用克拉屈滨/低剂量阿糖胞苷/维奈托克进行低强度治疗在老年急性髓系白血病患者中具有更好的效果。
Cancer. 2024 Oct 1;130(19):3333-3343. doi: 10.1002/cncr.35388. Epub 2024 May 29.
10
Combination therapy with novel agents for acute myeloid leukaemia: Insights into treatment of a heterogenous disease.新型药物联合治疗急性髓系白血病：异质性疾病治疗的新视角。
Br J Haematol. 2024 Jul;205(1):30-47. doi: 10.1111/bjh.19519. Epub 2024 May 9.